Nov 14, 2024 · We are Inhibikase Therapeutics, a pharmaceutical company innovating small-molecule kinase inhibitor therapeutics to treat Parkinson’s disease, Parkinson’s-related neurodegenerative diseases and other diseases caused by dysfunction of …

22 hours ago · Inhibikase’s stock price declined more than 19% in after-hours trading at $2.26 per share, down from $2.80 at the previous close. Risvodetinib’s discontinuation highlights the difficulties of developing effective therapies for Parkinson’s disease, a therapeutic space that has suffered several stumbles and even more abandoned assets in ...

21 hours ago · Inhibikase Therapeutics announced results from a Phase 2 trial of its Parkinson’s disease drug, risvodetinib, a selective inhibitor of the non-receptor Abelson tyrosine kinases, in a filing to the US Securities and Exchange Commission (SEC) this week.. While the drug met the trial endpoint for safety and tolerability, it did not significantly improve symptoms in …

1 day ago · Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic options” for the med after it came up short in the efficacy stakes.

Inhibikase Therapeutics develops treatments that seek to intervene in neurodegeneration where disease begins. Our treatments flow from a novel understanding of the etiology—cause or set of causes—of neurodegenerative diseases.

We have developed a platform prodrug technology that adds a small linker to a known or novel kinase inhibitor and suppresses on-dosing side effects common to drugs in this class, particularly gastrointestinal disturbance (nausea, diarrhea and/or vomiting).

2 days ago · Inhibikase Therapeutics said on Wednesday it would stop development of its experimental Parkinson's disease drug after it failed to improve patients' ability to carry out daily tasks such as ...

BOSTON and ATLANTA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase...

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a...

Feb 28, 2024 · Inhibikase's multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of...